Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCUSG3)

• Drug Name: NU6140 Drug Info
• Synonyms: Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, > RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10202471
  CAS Number: CAS 444723-13-1
  TTD Drug ID: DMCUSG3

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase EIF2AK2 (p68)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9650366, 12	DMR3Z49	N. A.	N. A.	Patented	[3]
US9650366, 2	DM9HZ03	N. A.	N. A.	Patented	[3]
US9650366, 9	DMUCIPE	N. A.	N. A.	Patented	[3]
ASN-11124542	DMFNZOI	Discovery agent	N.A.	Investigative	[4]
indirubin derivative E804	DMFP1C5	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Cyclin-dependent kinase 5 (CDK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[5]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[6]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[6]
4-(thiazol-5-yl)-pyrimidine derivative 2	DMMQFCN	N. A.	N. A.	Patented	[6]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	DMOK7CW	N. A.	N. A.	Patented	[6]
Naphthyridine and isoquinoline derivative 1	DMTGIP7	N. A.	N. A.	Patented	[6]
PMID26161698-Compound-18	DM6JVR5	N. A.	N. A.	Patented	[6]
Flavonoid derivative 7	DM6A9UR	N. A.	N. A.	Patented	[6]
L-751250	DMOERXK	Obesity	5B81	Preclinical	[7]
Olomoucine	DMNAFG1	N. A.	N. A.	Terminated	[7]

Drug(s) Targeting Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[8]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[8]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[10]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[11]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[13]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[14]

Drug(s) Targeting Cyclin-dependent kinase 7 (CDK7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[8]
Samuraciclib	DM54FQA	Breast cancer	2C60-2C65	Phase 1/2	[15]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[17]
SY-1365	DMK48PM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
LY3405105	DMB51K2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
SY-5609	DMNW3LH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[6]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[6]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[6]

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[8]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[21]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[22]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[23]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[11]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[24]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[25]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[26]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[27]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[28]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[29]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[30]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[8]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[31]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[18]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[32]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[33]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[34]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[35]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[36]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[37]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[38]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[41]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 1 (CDK1)	TTH6V3D	CDK1_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 4 (CDK4)	TT0PG8F	CDK4_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 5 (CDK5)	TTL4Q97	CDK5_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 7 (CDK7)	TTQYF7G	CDK7_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase EIF2AK2 (p68)	TTXEZJ4	E2AK2_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[1]

References

• [1] Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
• [2] Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4108-14.
• [3] Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366.
• [4] Small molecule inhibitors of the RNA-dependent protein kinase. Biochem Biophys Res Commun. 2003 Aug 15;308(1):50-7.
• [5] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [6] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [7] Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
• [8] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [9] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [10] P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
• [11] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [12] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [13] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [14] Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
• [15] The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337.
• [16] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [17] Clinical pipeline report, company report or official report of BioTheryX.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
• [20] Clinical pipeline report, company report or official report of Syros Pharmaceuticals.
• [21] Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
• [22] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [23] ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
• [24] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [25] Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
• [26] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [27] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [30] Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
• [31] Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
• [32] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [33] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [34] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [35] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [36] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [37] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [38] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [39] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [40] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [41] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.